Education
About Us
Working with TipRanks
Follow Us
Dimerix Limited (AU:DXB)
ASX:DXB
DXB Stock Chart & Stats
AU$0.54
-AU$0.03(-5.00%)
At close: 4:00 PM EST
AU$0.54
-AU$0.03(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.34 - AU$0.79
Previous CloseN/A
Volume4.60M
Average Volume (3M)1.47M
Market Cap
AU$324.21M
Enterprise ValueAU$275.96M
Total Cash (Recent Filing)AU$68.28M
Total Debt (Recent Filing)AU$97.48K
Price to Earnings (P/E)―
Beta2.63
Next Earnings
Mar 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding600,396,800
10 Day Avg. Volume1,720,426
30 Day Avg. Volume1,468,144
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)24.09
Price to Sales (P/S)256.86
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Dimerix Limited News
DXB FAQ
What was Dimerix Limited’s price range in the past 12 months?
Dimerix Limited lowest share price was AU$0.34 and its highest was AU$0.79 in the past 12 months.
What is Dimerix Limited’s market cap?
Dimerix Limited’s market cap is AU$324.21M.
When is Dimerix Limited’s upcoming earnings report date?
Dimerix Limited’s upcoming earnings report date is Mar 02, 2026 which is in 50 days.
How were Dimerix Limited’s earnings last quarter?
Dimerix Limited released its earnings results on Aug 27, 2025. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Dimerix Limited overvalued?
According to Wall Street analysts Dimerix Limited’s price is currently Overvalued.
Does Dimerix Limited pay dividends?
Dimerix Limited does not currently pay dividends.
What is Dimerix Limited’s EPS estimate?
Dimerix Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dimerix Limited have?
Dimerix Limited has 600,396,800 shares outstanding.
What happened to Dimerix Limited’s price movement after its last earnings report?
Dimerix Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Dimerix Limited?
Currently, no hedge funds are holding shares in AU:DXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dimerix Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AU:DXB Sentiment 97%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.10%
12-Months-Change
Fundamentals
Return on Equity
-83.97%
Trailing 12-Months
Asset Growth
184.23%
Trailing 12-Months
Company Description
Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Orthocell Ltd
―
Immutep Ltd
―
Race Oncology Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---